Jakarta, Japanese biopharmaceutical company Takeda plans to invest $30 million in the initial phase of a project to develop Indonesia's plasma-derived medicines ecosystem, Investment Minister Rosan Roeslani said on Tuesday.

The first-stage investment will be deployed over two years to establish a nationwide plasma collection network, laying the foundation for a domestic plasma processing industry.

Rosan said the project represents a strategic investment that goes beyond capital by supporting technology transfer, workforce development, and the creation of high-skilled jobs.

“The government continues to encourage investments that generate added value and strengthen national industrial capacity so Indonesia can become a regional hub for healthcare manufacturing and innovation,” Rosan said in a statement.

He added that Japan remains one of Indonesia's key investment partners.

According to the Investment Ministry, Japan ranked as Indonesia's fifth-largest foreign investor in the first quarter of 2026, with investment totaling $1 billion.

Since 2021, Japanese investment in Indonesia has reached $18.1 billion, growing at an average annual rate of 13.2% and generating employment for nearly 300,000 workers, ministry data show.

Rosan said the Takeda investment is expected to improve public access to plasma-derived medicines while helping establish a competitive, innovative, and sustainable domestic biopharmaceutical industry.

Indonesia aims to begin operating its first plasma bank in 2027 as part of a nationwide network designed to meet international standards.